Plain-English translation of NCT05356325 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how a naturally occurring protein in your body—called FGF23—might affect your heart when you have anemia (low red blood cells). This study will compare FGF23 levels in people with anemia who have normal kidney function to those who have anemia and early-stage kidney disease, to see if the protein plays a role in causing heart damage.
Anemia is known to stress the heart, and kidney disease can make this worse. Scientists suspect that FGF23 may be an important missing piece in understanding why some people with anemia develop heart problems—and identifying this connection could lead to new ways to protect heart health in these patients.
You likely qualify if…
You likely don't qualify if…
Your participation will involve providing a blood sample, which researchers will analyze to measure FGF23 and other markers related to anemia and heart health. The study will compare your results with those of other participants in similar situations. Beyond the blood draw, there are no medications to take or ongoing visits required—this is purely an observational study based on your medical information and lab work.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Spain
Fondo de Investigacion Sanitaria
Enrollment target
~401 participants
Started
October 2021
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Casimiro Valle Domínguez, MD
Maimónides Biomedical Research Institute of Córdoba
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.